Skip to main content
Top
Published in: Endocrine 3/2021

01-12-2021 | Original Article

Bone and body composition analyses by DXA in adults with GH deficiency: effects of long-term replacement therapy

Authors: Alessandro Rossini, Roberto Lanzi, Carlotta Galeone, Claudio Pelucchi, Mario Pennacchioni, Francesca Perticone, Marcella Sirtori, Marco Losa, Alessandro Rubinacci

Published in: Endocrine | Issue 3/2021

Login to get access

Abstract

Purpose

The effects of growth hormone (GH) replacement on bone mass and body composition in adult with GH deficiency (AGHD) are still debated with regard to their persistence in the long term. Moreover, the impact of the gender on the response to GH is controversial. Aim of this study was to evaluate the long-term effects of rhGH replacement on bone mass and body composition in a monocentric cohort of patients with AGHD.

Methods

Data from 118 patients with AGHD (34.8 ± 14.4 years, 43 women and 75 men) treated with rhGH for a period of at least 3 years up to a maximum of 10 were retrospectively collected. Bone mineral density (BMD) at the lumbar spine, femur, and 1/3 radius, and total and truncular body composition were evaluated by dual-energy X-ray absorption (DXA) before and during treatment. Clinical and laboratory evaluations were performed before and during the treatment period on an annual basis.

Results

Lumbar spine BMD consistently increased in males, while it decreased in females after a transient improvement observed during the first 4 years of therapy. There were no significant changes in femoral and 1/3 radial BMD in either sexes. Lean mass significantly increased in both sexes, while fat mass only decreased in males.

Conclusions

In AGHD patients long-term rhGH replacement therapy induces a positive effect with regard to bone mass and body composition. A sexual dimorphism in the response to treatment is evident, with males displaying a more favorable outcome.
Literature
1.
go back to reference K.K. Ho, Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157, 695e700 (2007)CrossRef K.K. Ho, Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157, 695e700 (2007)CrossRef
2.
go back to reference S.J. Holmes, G. Economou, R.W. Whitehouse et al. Reduced bone mineral density in patients with adult-onset growth hormone deficiency. J Clin Endocrinol Metab 78, 669e74 (1994) S.J. Holmes, G. Economou, R.W. Whitehouse et al. Reduced bone mineral density in patients with adult-onset growth hormone deficiency. J Clin Endocrinol Metab 78, 669e74 (1994)
3.
go back to reference B. Angelin, M. Rudling, Growth hormone and lipoprotein metabolism. Endocrinol Metab 2, 25–28 (1995) B. Angelin, M. Rudling, Growth hormone and lipoprotein metabolism. Endocrinol Metab 2, 25–28 (1995)
4.
go back to reference D.A. Fryburg, R.A. Gelfand, E.J. Barrett, Growth hormone acutely stimulates muscle protein synthesis in normal humans. Am J Physiol 260, E 499–E 504 (1991) D.A. Fryburg, R.A. Gelfand, E.J. Barrett, Growth hormone acutely stimulates muscle protein synthesis in normal humans. Am J Physiol 260, E 499–E 504 (1991)
5.
go back to reference D.M. Hoffman, R. Pallasser, M. Duncan et al. How is whole body protein turnover perturbed in growth hormone deficient adults? J Clin Endocrinol Metab 83, 4344–4349 (1998)PubMed D.M. Hoffman, R. Pallasser, M. Duncan et al. How is whole body protein turnover perturbed in growth hormone deficient adults? J Clin Endocrinol Metab 83, 4344–4349 (1998)PubMed
6.
go back to reference N.A. Tritos, Focus on growth hormone deficiency and bone in adults. Best Pract Res Clin Endocrinol Metab 31, 49–57 (2017)CrossRef N.A. Tritos, Focus on growth hormone deficiency and bone in adults. Best Pract Res Clin Endocrinol Metab 31, 49–57 (2017)CrossRef
7.
go back to reference G. Mazziotti, M. Doga, S. Frara, F. Maffezzoni, T. Porcelli, L. Cerri, R. Maroldi, A. Giustina, Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine. 52, 103–110 (2016)CrossRef G. Mazziotti, M. Doga, S. Frara, F. Maffezzoni, T. Porcelli, L. Cerri, R. Maroldi, A. Giustina, Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine. 52, 103–110 (2016)CrossRef
8.
go back to reference J. Isgaard, M. Arcopinto, K. Karason, A. Cittadini, GH and the cardiovascular system: an update on a topic at heart. Endocrine 48, 25–35 (2015)CrossRef J. Isgaard, M. Arcopinto, K. Karason, A. Cittadini, GH and the cardiovascular system: an update on a topic at heart. Endocrine 48, 25–35 (2015)CrossRef
9.
go back to reference D. Mo, M. Fleseriu, R. Qi, N. Jia, C.J. Child, R. Bouillon, D.S. Hardin, Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol 3, 331–338 (2015)CrossRef D. Mo, M. Fleseriu, R. Qi, N. Jia, C.J. Child, R. Bouillon, D.S. Hardin, Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol 3, 331–338 (2015)CrossRef
10.
go back to reference P. Chanson, The heart in growth hormone (GH) deficiency and the cardiovascular effects of GH. Ann Endocrinol S0003-4266, 30040–30048 (2020). Online ahead of print P. Chanson, The heart in growth hormone (GH) deficiency and the cardiovascular effects of GH. Ann Endocrinol S0003-4266, 30040–30048 (2020). Online ahead of print
11.
go back to reference C. Franco, J. Koranyi, J. Brandberg, L. Löon, B.K. Bengtsson, J. Svensson, G. Johannsson, The reduction in visceral fat mass in response to growth hormone is more marked in men than in oestrogen deficient women. Growth Horm IGF Res 19, 112–120 (2009)CrossRef C. Franco, J. Koranyi, J. Brandberg, L. Löon, B.K. Bengtsson, J. Svensson, G. Johannsson, The reduction in visceral fat mass in response to growth hormone is more marked in men than in oestrogen deficient women. Growth Horm IGF Res 19, 112–120 (2009)CrossRef
14.
go back to reference P. Maison, P. Chanson, Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108, 2648–2652 (2003)CrossRef P. Maison, P. Chanson, Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108, 2648–2652 (2003)CrossRef
15.
go back to reference A. Ziagaki, D. Blaschke, W. Haverkamp, U. Plöckinger, Long-term growth hormone (GH) replacement of adult GH deficiency (GHD) benefits the heart. Eur J Endocrinol 181(Jul 1), 79–91 (2019)CrossRef A. Ziagaki, D. Blaschke, W. Haverkamp, U. Plöckinger, Long-term growth hormone (GH) replacement of adult GH deficiency (GHD) benefits the heart. Eur J Endocrinol 181(Jul 1), 79–91 (2019)CrossRef
16.
go back to reference N.M. Appelman-Dijkstra, K.M. Claessen, N.A. Hamdy et al. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. Clin Endocrinol 81, 727e35 (2014)CrossRef N.M. Appelman-Dijkstra, K.M. Claessen, N.A. Hamdy et al. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. Clin Endocrinol 81, 727e35 (2014)CrossRef
17.
go back to reference M. Barake, A. Klibanski, N.A. Tritos, Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab 99, 852e60 (2014)CrossRef M. Barake, A. Klibanski, N.A. Tritos, Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab 99, 852e60 (2014)CrossRef
18.
go back to reference A.L. Carrel, D.B. Allen, Effects of growth hormone on body composition and bone metabolism. Endocrine 12(2), 163–172 (2000)CrossRef A.L. Carrel, D.B. Allen, Effects of growth hormone on body composition and bone metabolism. Endocrine 12(2), 163–172 (2000)CrossRef
19.
go back to reference P. Davidson, R. Milne, D. Chase et al. Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. Clin Endocrinol 60, 92e8 (2004)CrossRef P. Davidson, R. Milne, D. Chase et al. Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. Clin Endocrinol 60, 92e8 (2004)CrossRef
20.
go back to reference M. Elbornsson, G. Gotherstrom, I. Bosaeus et al. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 166, 787–795 (2012)CrossRef M. Elbornsson, G. Gotherstrom, I. Bosaeus et al. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 166, 787–795 (2012)CrossRef
21.
go back to reference M. Elbornsson, G. Gotherstrom, I. Bosæus, B.A. Bengtsson, G. Johannsson, J. Svensson, Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol 168, 745–753 (2013)CrossRef M. Elbornsson, G. Gotherstrom, I. Bosæus, B.A. Bengtsson, G. Johannsson, J. Svensson, Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol 168, 745–753 (2013)CrossRef
22.
go back to reference A. Rossini, R. Lanzi, M. Losa et al. Predictors of bone responsiveness to growth hormone (GH) replacement in adult GH-deficient patients. Calcif Tissue Int 88, 304–313 (2011)CrossRef A. Rossini, R. Lanzi, M. Losa et al. Predictors of bone responsiveness to growth hormone (GH) replacement in adult GH-deficient patients. Calcif Tissue Int 88, 304–313 (2011)CrossRef
23.
go back to reference G. Götherström, B.A. Bengtsson, I. Bosaeus, G. Johannsson, J. Svensson, G.H. Ten-year, replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 156, 55–64 (2007)CrossRef G. Götherström, B.A. Bengtsson, I. Bosaeus, G. Johannsson, J. Svensson, G.H. Ten-year, replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 156, 55–64 (2007)CrossRef
24.
go back to reference N.A. Tritos, A.H. Hamrahian, D. King, S.L. Greenspan, D.M. Cook, P.J. Jönsson, M. Koltowska-Häggstrom, B.M. Biller, Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency – a KIMS database analysis. Clin Endocrinol 79, 178–184 (2013)CrossRef N.A. Tritos, A.H. Hamrahian, D. King, S.L. Greenspan, D.M. Cook, P.J. Jönsson, M. Koltowska-Häggstrom, B.M. Biller, Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency – a KIMS database analysis. Clin Endocrinol 79, 178–184 (2013)CrossRef
25.
go back to reference G. Corneli, C. Di Somma, R. Baldelli et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 153(2), 257–264 (2005)CrossRef G. Corneli, C. Di Somma, R. Baldelli et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 153(2), 257–264 (2005)CrossRef
26.
go back to reference S. Baim, N. Binkley, J.P. Bilezikian, D.L. Kendler, D.B. Hans, E.M. Lewiecki, S. Silverman, Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 11, 75–791 (2008)CrossRef S. Baim, N. Binkley, J.P. Bilezikian, D.L. Kendler, D.B. Hans, E.M. Lewiecki, S. Silverman, Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 11, 75–791 (2008)CrossRef
28.
go back to reference M.L. Bouxsein, R. Eastell, L.Y. Lui, L.A. Wu, A.E. de Papp, A. Grauer, F. Marin, J.A. Cauley, D.C. Bauer, D.M. Black, FNIH Bone Quality Project. Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34, 632–642 (2019). https://doi.org/10.1002/jbmr.3641CrossRefPubMed M.L. Bouxsein, R. Eastell, L.Y. Lui, L.A. Wu, A.E. de Papp, A. Grauer, F. Marin, J.A. Cauley, D.C. Bauer, D.M. Black, FNIH Bone Quality Project. Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34, 632–642 (2019). https://​doi.​org/​10.​1002/​jbmr.​3641CrossRefPubMed
29.
go back to reference G. Gotherstrom, J. Svensson, J. Koranyi, M. Alpsten, I. Bosaeus, B. Bengtsson, G. Johannsson, A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 86, 4657–4665 (2001)CrossRef G. Gotherstrom, J. Svensson, J. Koranyi, M. Alpsten, I. Bosaeus, B. Bengtsson, G. Johannsson, A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 86, 4657–4665 (2001)CrossRef
31.
go back to reference R. Lanzi, M. Losa, I. Villa, E. Gatti, M. Sirtori, F.C. Dal, A. Rubinacci, GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. Eur J Endocrinol 148, 185–191 (2003)CrossRef R. Lanzi, M. Losa, I. Villa, E. Gatti, M. Sirtori, F.C. Dal, A. Rubinacci, GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. Eur J Endocrinol 148, 185–191 (2003)CrossRef
32.
go back to reference E. Mrak, I. Villa, R. Lanzi, M. Losa, F. Guidobono, A. Rubinacci, Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells. J Endocrinol 192, 639–645 (2007)CrossRef E. Mrak, I. Villa, R. Lanzi, M. Losa, F. Guidobono, A. Rubinacci, Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells. J Endocrinol 192, 639–645 (2007)CrossRef
33.
go back to reference B. Abrahamsen, J. Hangaard, H.C. Horn, T.B. Hansen, G. Gregersen, M. Hansen- Nord, N. Vahl, P. Junker, M. Andersen, C. Hagen, Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies. Clin Endocrinol 57, 273–281 (2002)CrossRef B. Abrahamsen, J. Hangaard, H.C. Horn, T.B. Hansen, G. Gregersen, M. Hansen- Nord, N. Vahl, P. Junker, M. Andersen, C. Hagen, Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies. Clin Endocrinol 57, 273–281 (2002)CrossRef
35.
go back to reference Z. Pekkolay, F. Kılınç, N. Gozel, E. Önalan, A.K. Tuzcu, Increased serum sclerostin levels in patients with active Acromegaly. J Clin Endocrinol Metab 105, dgz254 (2020)CrossRef Z. Pekkolay, F. Kılınç, N. Gozel, E. Önalan, A.K. Tuzcu, Increased serum sclerostin levels in patients with active Acromegaly. J Clin Endocrinol Metab 105, dgz254 (2020)CrossRef
36.
go back to reference M.R. Laurent, V. Dubois, F. Claessens, S.M.P. Verschueren, D. Vanderschueren, E. Gielen, F. Jardí, Muscle-bone interactions: From experimental models to the clinic? A critical update. Mol Cell Endocrinol 432, 14e36 (2016)CrossRef M.R. Laurent, V. Dubois, F. Claessens, S.M.P. Verschueren, D. Vanderschueren, E. Gielen, F. Jardí, Muscle-bone interactions: From experimental models to the clinic? A critical update. Mol Cell Endocrinol 432, 14e36 (2016)CrossRef
37.
go back to reference H. Kaji, Effects of myokines on bone. Bonekey Rep 826, 1038–1044 (2016) H. Kaji, Effects of myokines on bone. Bonekey Rep 826, 1038–1044 (2016)
39.
go back to reference M.R. Postma, A.P. van Beek, P.J. Jönsson, C.C. van Bunderen, M.L. Drent, A.F. Mattsson, C. Camacho-Hubner, Improvements in body composition after 4 years of growth hormone treatment in adult-onset hypopituitarism compared to age-matched controls. Neuroendocrinology 109(2), 131–140 (2019)CrossRef M.R. Postma, A.P. van Beek, P.J. Jönsson, C.C. van Bunderen, M.L. Drent, A.F. Mattsson, C. Camacho-Hubner, Improvements in body composition after 4 years of growth hormone treatment in adult-onset hypopituitarism compared to age-matched controls. Neuroendocrinology 109(2), 131–140 (2019)CrossRef
40.
go back to reference V. Birzniece, K.K. Ho, Sex steroids and the GH axis: implications for the management of hypopituitarism. Best Pract Res Clin Endocrinol Metabol 31, 59–69 (2017)CrossRef V. Birzniece, K.K. Ho, Sex steroids and the GH axis: implications for the management of hypopituitarism. Best Pract Res Clin Endocrinol Metabol 31, 59–69 (2017)CrossRef
41.
go back to reference J. Gibney, T. Wolthers, G. Johannsson, A.M. Umpleby, K.K. Ho, Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. Am J Physiol Endocrinol Metab 289, E266–E271 (2005)CrossRef J. Gibney, T. Wolthers, G. Johannsson, A.M. Umpleby, K.K. Ho, Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. Am J Physiol Endocrinol Metab 289, E266–E271 (2005)CrossRef
42.
43.
go back to reference D. Bikle, S. Majumdar, A. Laib, L. Powell-Braxton, C. Rosen, W. Beamer, E. Nauman, C. Leary, B. Halloran, The skeletal structure of insulin-like growth factor I-deficient mice. J Bone Miner Res 16, 2320–2329 (2001)CrossRef D. Bikle, S. Majumdar, A. Laib, L. Powell-Braxton, C. Rosen, W. Beamer, E. Nauman, C. Leary, B. Halloran, The skeletal structure of insulin-like growth factor I-deficient mice. J Bone Miner Res 16, 2320–2329 (2001)CrossRef
44.
go back to reference G. Zhao, M.C. Monier-Faugere, M.C. Langub, Z. Geng, T. Nakayama, J.W. Pike, S.D. Chernausek, C.J. Rosen, L.R. Donahue, H.H. Malluche, J.A. Fagin, T.L. Clemens, Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 141, 2674–2682 (2000)CrossRef G. Zhao, M.C. Monier-Faugere, M.C. Langub, Z. Geng, T. Nakayama, J.W. Pike, S.D. Chernausek, C.J. Rosen, L.R. Donahue, H.H. Malluche, J.A. Fagin, T.L. Clemens, Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 141, 2674–2682 (2000)CrossRef
45.
go back to reference K.M. Claessen, N.M. Appelman-Dijkstra, D.M. Adoptie, F. Roelfsema, J.W. Smit, N.R. Biermasz, A.M. Pereira, Metabolic profile in growth hormone- deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab 98(1), 352–361 (2013)CrossRef K.M. Claessen, N.M. Appelman-Dijkstra, D.M. Adoptie, F. Roelfsema, J.W. Smit, N.R. Biermasz, A.M. Pereira, Metabolic profile in growth hormone- deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab 98(1), 352–361 (2013)CrossRef
Metadata
Title
Bone and body composition analyses by DXA in adults with GH deficiency: effects of long-term replacement therapy
Authors
Alessandro Rossini
Roberto Lanzi
Carlotta Galeone
Claudio Pelucchi
Mario Pennacchioni
Francesca Perticone
Marcella Sirtori
Marco Losa
Alessandro Rubinacci
Publication date
01-12-2021
Publisher
Springer US
Published in
Endocrine / Issue 3/2021
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-021-02835-6

Other articles of this Issue 3/2021

Endocrine 3/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.